Eli Lilly $LLY missed Q3 forecast. For the concluded quarter, revenue was $5.19 billion, a growth of 4.6%, Y-o-Y, but falling short of the forecast by $100 million. EPS for the quarter stood at $0.88, missing estimates by $0.07. The company expects fiscal 2016 EPS to come in the range of $2.66 to $2.76. On a non-GAAP basis the company reiterated 2016 EPS to be in the range of $3.50 to $3.60. It said that significant drug-pipeline progress continued with the FDA approving Lartruvo and Fast Track designation for BACE inhibitor AZD3293, as well as positive opinions from Europe�s CHMP for Lartruvo and Glyxambi.